UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 285

Sortiert nach

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2015-08, Vol.373 (8), p.737-746

2015

Volltextzugriff (PDF)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

Low-Fat Abiraterone Food Effect Is of Little Consequence

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1385-1386

2018

Volltextzugriff (PDF)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

European urology, 2016-12, Vol.70 (6), p.963-970

2016

Volltextzugriff (PDF)

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

JNCI : Journal of the National Cancer Institute, 2010-05, Vol.102 (9), p.596-604

2010

Volltextzugriff (PDF)

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Clinical cancer research, 2009-05, Vol.15 (9), p.3172-3176

2009

Volltextzugriff (PDF)

Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4047-4054

2009

Volltextzugriff (PDF)

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5474-5483

2005

Volltextzugriff (PDF)

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

Clinical cancer research, 2011-12, Vol.17 (24), p.7634-7644

2011

Volltextzugriff (PDF)

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Clinical cancer research, 2008-12, Vol.14 (23), p.7940-7946

2008

Volltextzugriff (PDF)

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Clinical cancer research, 2014-07, Vol.20 (14), p.3692-3704

2014

Volltextzugriff (PDF)

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Clinical cancer research, 2009-02, Vol.15 (4), p.1460-1465

2009

Volltextzugriff (PDF)

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Journal for immunotherapy of cancer, 2023-12, Vol.11 (12), p.e008067

2023

Volltextzugriff (PDF)

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer

Molecular oncology, 2022-12, Vol.16 (22), p.3994-4010

2022

Volltextzugriff (PDF)

FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.23-23, Article 23

2019

Volltextzugriff (PDF)

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5464-5473

2005

Volltextzugriff (PDF)

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

Clinical cancer research, 2005-09, Vol.11 (18), p.6625-6633

2005

Volltextzugriff (PDF)

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Clinical cancer research, 2008-08, Vol.14 (15), p.4836-4842

2008

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab

The Journal of nuclear medicine (1978), 2017-01, Vol.58 (1), p.162-168

2017

Volltextzugriff (PDF)

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

The Journal of nuclear medicine (1978), 2016-12, Vol.57 (12), p.1872-1879

2016

Volltextzugriff (PDF)

Endothelin Receptor Antagonists in Cancer Therapy

Cancer investigation, 2007-12, Vol.25 (8), p.785-794

2007

Volltextzugriff (PDF)

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

Clinical cancer research, 2008-04, Vol.14 (8), p.2437-2443

2008

Volltextzugriff (PDF)

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

Urologic oncology, 2013-02, Vol.31 (2), p.211-218

2013

Volltextzugriff (PDF)

High resolution ultrasound features of prostatic rib metastasis: A prospective feasibility study with implication in the high-risk prostate cancer patient

Urologic oncology, 2014-01, Vol.32 (1), p.24.e7-24.e11

2014

Volltextzugriff (PDF)

1 – 25 von 285

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(259)

Publikationsform

Artikel
(285)

Sprache

Englisch
(285)
Japanisch
(49)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(16)
Investigational New Drugs
(12)
Plos One
(12)
Journal Of Clinical Oncology
(10)
Cancer Chemotherapy And Pharmacology
(9)
Clinical Genitourinary Cancer
(7)
The New England Journal Of Medicine
(5)
Cancer
(4)
Blood
(3)
European Urology
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Low-Fat Abiraterone Food Effect Is of Little Consequence

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer

FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Endothelin Receptor Antagonists in Cancer Therapy

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

High resolution ultrasound features of prostatic rib metastasis: A prospective feasibility study with implication in the high-risk prostate cancer patient

Aktive Filter

Suchergebnisse filtern